Please try another search
For the nine months ended 30 September 2016,Advanced Pharmaceutical Pckgng Comp SAE revenues increasedfrom EGP0K to EGP1.2M. Net loss decreased 91% to EGP1.3M.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Lower net loss reflects Other Income increase from EGP15Kto EGP1.6M (income), Total Financial Expense decrease fromEGP1K (expense) to EGP0K.
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Revenue | 0.34 | 0.86 | 0.04 | 0 |
Gross Profit | 0.06 | 0.11 | -0.11 | -8.42 |
Operating Income | -0.29 | -2.37 | -0.85 | -57.37 |
Net Income | 1.24 | -2.57 | -0.93 | -57.46 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Assets | 73.51 | 73.66 | 73.98 | 74.15 |
Total Liabilities | 28.07 | 28.27 | 28.13 | 27.38 |
Total Equity | 45.44 | 45.39 | 45.85 | 46.77 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -1.81 | 0.1 | 0 | -31.72 |
Cash From Investing Activities | 1.83 | 0 | 0 | 28.73 |
Cash From Financing Activities | 0 | 0 | 0 | 2.8 |
Net Change in Cash | 0.01 | 0.1 | 0 | -0.2 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review